- freely available
The “Connection” Between HIV Drug Resistance and RNase H
AbstractCurrently, nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) are two classes of antiretroviral agents that are approved for treatment of HIV-1 infection. Since both NRTIs and NNRTIs target the polymerase (pol) domain of reverse transcriptase (RT), most genotypic analysis for drug resistance is limited to the first ~300 amino acids of RT. However, recent studies have demonstrated that mutations in the C-terminal domain of RT, specifically the connection subdomain and RNase H domain, can also increase resistance to both NRTIs and NNRTIs. In this review we will present the potential mechanisms by which mutations in the C-terminal domain of RT influence NRTI and NNRTI susceptibility, summarize the prevalence of the mutations in these regions of RT identified to date, and discuss their importance to clinical drug resistance.
Share & Cite This Article
Delviks-Frankenberry, K.A.; Nikolenko, G.N.; Pathak, V.K. The “Connection” Between HIV Drug Resistance and RNase H. Viruses 2010, 2, 1476-1503.View more citation formats
Delviks-Frankenberry KA, Nikolenko GN, Pathak VK. The “Connection” Between HIV Drug Resistance and RNase H. Viruses. 2010; 2(7):1476-1503.Chicago/Turabian Style
Delviks-Frankenberry, Krista A.; Nikolenko, Galina N.; Pathak, Vinay K. 2010. "The “Connection” Between HIV Drug Resistance and RNase H." Viruses 2, no. 7: 1476-1503.
Notes: Multiple requests from the same IP address are counted as one view.